SCHEMBL3460205

SCHEMBL3460205

Cc1cc(NC(=O)Nc2ccccc2)ccc1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.57
TP53 P04637 2/20 0.57
EPHX1 P07099 1/20 0.57
TSHR P16473 1/20 0.57
EPHX2 P34913 1/20 0.57
CDK9 P50750 1/20 0.57
CLK4 Q9HAZ1 1/20 0.57
NPC1 O15118 8/20 0.56
RAB9A P51151 7/20 0.56
KMT2A Q03164 6/20 0.56
MAPT P10636 6/20 0.56
MEN1 O00255 5/20 0.56
LMNA P02545 3/20 0.56
MAPK1 P28482 2/20 0.56
MAOA P21397 2/20 0.56
MAOB P27338 2/20 0.56
TAAR1 Q96RJ0 2/20 0.56
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
HTT P42858 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504525 0.87 NPC1 (0.60) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL3460675 0.86 DDX3X (0.69) SMN1; SMN2TP53NPC1RAB9AKMT2A
SCHEMBL11594185 0.85 MEN1 (0.58) SMN1; SMN2EPHX1EPHX2NPC1RAB9A
SCHEMBL1654638 0.84 ALDH1A1 (0.55) TSHRNPC1RAB9AKMT2AMAPT
SCHEMBL23292684 0.83 CYP1A2 (0.71) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL18921090 0.83 NPC1 (0.67) SMN1; SMN2NPC1RAB9AKMT2AMAPT
SCHEMBL21247829 0.83 ALDH1A1 (0.50) TSHRNPC1RAB9AKMT2AMAPT
SCHEMBL3530325 0.82 KMT2A (0.69) SMN1; SMN2TP53NPC1RAB9AKMT2A
SCHEMBL10242035 0.81 MAOA (0.59) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL3461528 0.81 NPC1 (0.54) SMN1; SMN2TP53EPHX1TSHREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B SMN1; SMN2 3298/4885TP53 2060/4885EPHX1 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.